Skip to Main content
New interface

Social networks

    Number of documents

    25

    Nicolas Azzopardi


    Journal articles24 documents

    • David Tougeron, Sheik Emambux, Laure Favot, Thierry Lecomte, Ewa Wierzbicka-Hainaut, et al.. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). OncoImmunology, Taylor & Francis, 2020, 9 (1), 15 p. ⟨10.1080/2162402X.2020.1848058⟩. ⟨hal-03149030⟩
    • Thomas Secher, Emilie Dalonneau, Marion Ferreira, Christelle Parent, Nicolas Azzopardi, et al.. In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration. Journal of Controlled Release, Elsevier, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩. ⟨hal-02179896⟩
    • Amina Bensalem, Denis Mulleman, Gilles Paintaud, Nicolas Azzopardi, Valerie Gouilleux-Gruart, et al.. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clinical Pharmacokinetics, Springer Verlag, 2019, ⟨10.1007/s40262-019-00826-5⟩. ⟨hal-02316414⟩
    • Amina Bensalem, Denis Mulleman, Gilles Thibault, Nicolas Azzopardi, Philippe Goupille, et al.. CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, Wiley, 2019, ⟨10.1111/bcp.14102⟩. ⟨hal-02376303⟩
    • David Ternant, Nicolas Azzopardi, William Raoul, Theodora Bejan-Angoulvant, Gilles Paintaud. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. Clinical Pharmacokinetics, Springer Verlag, In press, ⟨10.1007/s40262-018-0680-3⟩. ⟨hal-01821717⟩
    • Yoann Pointreau, Nicolas Azzopardi, David Ternant, Gilles Calais, Gilles Paintaud. Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2017, pp.567-72. ⟨10.1097/FTD.0000000000000321⟩. ⟨hal-01769813⟩
    • Christophe Arnoult, Guillaume Brachet, Diana Cadena Castaneda, Nicolas Azzopardi, Christophe Passot, et al.. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice. Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩. ⟨hal-02019721⟩
    • Mira Tout, Anne-Laure Gagez, Stéphane Lepretre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, et al.. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, Springer Verlag, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩. ⟨hal-01769807⟩
    • Morgane Caulet, Thierry Lecomte, Olivier Bouché, Jérôme Rollin, Valérie Gouilleux-Gruart, et al.. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics, Springer Verlag, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩. ⟨hal-01769811⟩
    • David Ternant, Konstantinos Karmiris, Séverine Vermeire, Celine Desvignes, Nicolas Azzopardi, et al.. Pharmacokinetics of adalimumab in Crohn’s disease. European Journal of Clinical Pharmacology, Springer Verlag, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩. ⟨hal-01769822⟩
    • Nicolas Azzopardi, Sophie Dupuis-Girod, David Ternant, Anne-Emmanuelle Fargeton, Isabelle Ginon, et al.. Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. mAbs, Taylor & Francis, 2015, 7 (3), pp.630 - 637. ⟨10.1080/19420862.2015.1022693⟩. ⟨hal-01769884⟩
    • Jérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, Michelle Boisdron-Celle, Nicolas Azzopardi, et al.. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics, Future Medicine, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩. ⟨hal-02381189⟩
    • Virginie Herve, Nathalie Rabbe, Laurent Guilleminault, Flora Paul, Laurène Schlick, et al.. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. mAbs, Taylor & Francis, 2014, 6 (6), pp.1638 - 1648. ⟨10.4161/mabs.34454⟩. ⟨hal-01769888⟩
    • Laurent Guilleminault, Nicolas Azzopardi, Christophe Arnoult, Julien Sobilo, Virginie Hervé, et al.. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. Journal of Controlled Release, Elsevier, 2014, 196, pp.344-354. ⟨10.1016/j.jconrel.2014.10.003⟩. ⟨hal-02376374⟩
    • Christophe Passot, Nicolas Azzopardi, Sylvaine Renault, Nadine Baroukh, Christophe Arnoult, et al.. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. mAbs, Taylor & Francis, 2014, 5 (4), pp.614 - 619. ⟨10.4161/mabs.24815⟩. ⟨hal-01769897⟩
    • Nicolas Azzopardi, Maud François, Emeline Laurent, Gilles Paintaud, Béatrice Birmelé. Influence of plasma exchange on rituximab pharmacokinetics. British Journal of Clinical Pharmacology, Wiley, 2013, 76 (3), pp.486 - 488. ⟨10.1111/bcp.12167⟩. ⟨hal-01769901⟩
    • Agnes Maillet, Laurent Guilleminault, Etienne Lemarié, Stephanie Lerondel, Nicolas Azzopardi, et al.. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩. ⟨hal-01769936⟩
    • Nicolas Azzopardi, Therry Lecomte, David Ternant, Michele Boisdron-Celle, Friedrich Piller, et al.. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Fundamental & Clinical Pharmacology, Wiley, 2011, 25, pp.34-34. ⟨hal-00616314⟩
    • Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, et al.. Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients. Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩. ⟨hal-01769933⟩
    • D Chu Miow Lin, D. Mulleman, N. Azzopardi, G Griffoul-Espitalier, P Valat, et al.. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scandinavian Journal of Rheumatology, Taylor & Francis, 2010, 39 (1), pp.97 - 98. ⟨10.3109/03009740903177745⟩. ⟨hal-01769938⟩
    • D. Chu Miow Lin, D. Mulleman, N. Azzopardi, I. Griffoul-Espitalier, J.-P. Valat, et al.. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scandinavian Journal of Rheumatology, Taylor & Francis, 2010, 39 (1), pp.97-98. ⟨hal-00616813⟩
    • Agnes Maillet, Laurent Guilleminault, Nicolas Azzopardi, Jerome Montharu, Laurent Vecellio, et al.. Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab. Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2009, 4 (9), pp.S600-S600. ⟨hal-00616858⟩
    • Nicolas Ceze, David Ternant, Friedrich Piller, Danielle Degenne, Nicolas Azzopardi, et al.. An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2009, 31 (5), pp.597-601. ⟨hal-00521871⟩
    • Juliette Thariat, Nicolas Azzopardi, Frederic Peyrade, Vincent Launay-Vacher, Jose Santini, et al.. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. Journal of Clinical Oncology, American Society of Clinical Oncology, 2008, 26 (25), pp.4223-4225. ⟨hal-00616934⟩

    Conference poster1 document

    • A Bensalem, D Ternant, N. Azzopardi, G. Paintaud, V Gouilleux-Gruart, et al.. Relationship between rituximab concentration and autoantibody levels in anti-neutrophil cytoplasmic antibody associated vasculitis. EULAR 2019, Jun 2019, MADRID, Spain. ⟨hal-02149477⟩